2024
Topical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances.
Del Rosso J, Bunick C, Kircik L, Bhatia N. Topical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances. Journal Of Drugs In Dermatology 2024, 23: 438-445. PMID: 38834223, DOI: 10.36849/jdd.8318.Peer-Reviewed Original ResearchMeSH KeywordsAcne VulgarisAdministration, CutaneousAnti-Bacterial AgentsClindamycinDrug Resistance, BacterialHumansTreatment OutcomeConceptsAcne vulgarisTopical clindamycinTreatment of acne vulgarisManagement of acne vulgarisEmergence of antibiotic-resistant bacteriaAntibiotic-resistant bacteriaTopical agentsAnti-inflammatory propertiesTherapeutic advancesClindamycinClinical studiesTherapeutic outcomesClinical applicationAntimicrobial profileGram-positive bacteriaAnaerobic bacteriaMode of actionVulgarisMonotherapyPublished dataBacteriaTherapyAcneAntibiotics
2023
Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study
Bunick C, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D. Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study. Clinical And Experimental Dermatology 2023, 48: 765-769. PMID: 36928932, DOI: 10.1093/ced/llad105.Peer-Reviewed Original ResearchConceptsBSA involvementCongenital ichthyosisHigher DLQIIgA responsesTreatment successControl studyDermatology Life Quality Index scoresBody surface area involvementDose-limiting adverse effectGlobal assessmentLife Quality Index scoresInvestigator's Global AssessmentSurface area involvementProportion of participantsRating Scale scoresSystemic retinoid treatmentYears of ageQuality Index scoresCharacteristics of participantsIgA respondersBaseline demographicsEfficacy endpointMedian ageArea involvementScale score
2022
JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies.
Daniele S, Bunick C. JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies. Journal Of Drugs In Dermatology 2022, 21: 1298-1303. PMID: 36468956, DOI: 10.36849/jdd.7187.Peer-Reviewed Original ResearchMeSH KeywordsDermatitis, AtopicHumansImmunosuppression TherapyJanus Kinase InhibitorsSkin NeoplasmsTreatment OutcomeVenous ThromboembolismConceptsIncidence of adverse eventsAdverse cardiac eventsNon-melanoma skin cancerSystemic therapyAdverse eventsAtopic dermatitisCardiac eventsJAK inhibitorsVenous thromboembolismControl patientsSkin cancerIncidence rateTreatment of atopic dermatitisSystemic immunosuppressive therapyRates of non-melanoma skin cancerTraditional systemic therapiesIncidence of malignancyLong-term clinical trial dataReference control populationAtopic dermatitis treatmentBaseline rateLow incidence rateClinical trial dataImmunosuppressive therapySystemic corticosteroids
2021
Sarecycline treatment for acne vulgaris: Rationale for weight‐based dosing and limited impact of food intake on clinical efficacy
Grada A, Del Rosso JQ, Graber E, Bunick CG, Gold L, Moore AY, Baldwin H, Obagi Z, Damiani G, Carrothers T, McNamee B, Hanze E. Sarecycline treatment for acne vulgaris: Rationale for weight‐based dosing and limited impact of food intake on clinical efficacy. Dermatologic Therapy 2021, 35: e15275. PMID: 34923732, PMCID: PMC9286649, DOI: 10.1111/dth.15275.Peer-Reviewed Original ResearchMeSH KeywordsAcne VulgarisAdministration, OralAnti-Bacterial AgentsEatingHumansMinocyclineTetracyclinesTreatment OutcomeConceptsTetracycline-class antibioticsWeight-based dosingHigh-fat mealClinical efficacyAcne vulgarisFood intakeWeight-based dosing protocolAcne vulgaris patientsLow clinical efficacyExposure-response modelingPopulation pharmacokinetic modelingAcne vulgaris treatmentHigh-fat foodsDosing protocolDosing recommendationsInflammatory lesionsVulgaris patientsExtent of exposureClinical studiesImproved complianceGastrointestinal absorptionVulgaris treatmentDrug AdministrationPharmacokinetic modelingEfficacy